3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

About this Video

• Video Title: 3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore
• Channel: MarketBeat
• Speakers: Chris Markoch, Bridget (presumably the host)
• Duration: 00:17:23

Introduction

This MarketBeat video discusses three small-cap biotech stocks with significant growth potential. The hosts highlight the volatility of the biotech sector, particularly in the small-cap space, but emphasize the potential for high returns if investors understand the key factors, such as FDA approvals and clinical trial milestones. The video features a discussion of these factors and introduces MarketBeat's free FDA tracker tool.

Key Takeaways

• Biotech investing is volatile: Small-cap biotech stocks are particularly risky due to their dependence on clinical trial success and FDA approvals. Significant price swings are common.
• FDA approvals are crucial: FDA milestones (e.g., phase 1, 2, 3 trials, approvals) are major catalysts for biotech stock prices. Positive news drives prices up, while negative news can lead to significant drops.
• MarketBeat's FDA tracker: MarketBeat offers a free tool to track FDA events for biotech companies, aiding investor research and decision-making. This tool allows investors to screen for companies, drugs, and view recent events impacting stock prices.
• Three small-cap biotech stocks: The video features Eurogen (focus on urologic cancers, expanding label for Gel Milo), Nectar Therapeutics (NKTR, positive phase 2b clinical trial results for lupus and ulcerative colitis, fast-track designation), and Verve Therapeutics (VERV, gene editing therapy for cardiovascular disease, phase 1B US clinical trial underway). Each stock has varying levels of risk and projected growth potential based on analyst predictions.
• Long-term vs. short-term investment: While short-term traders might try to time trades around FDA announcements, long-term investors are advised to focus on companies with potentially game-changing drugs and ride out the market volatility.